Penile Vascular Abnormalities in Young Men with Persistent Side Effects After Finasteride Use for the Treatment of Androgenic Alopecia

    Mohit Khera, Jeffrey K. Than, James Anaissie, Ali Antar, Weitao Song, Boriss Losso, Alexander W. Pastuszak, Taylor P. Kohn, Jorge Rivera Mirabal
    Image of study
    TLDR Finasteride for hair loss may cause lasting sexual, genitourinary, mental, and anti-androgenic side effects in young men.
    The study investigated the persistent side effects of finasteride use for androgenic alopecia in young men. The study found that the use of 5-alpha reductase inhibitors (5ARI) for AGA may lead to persistent sexual, genitourinary, psycho-cognitive, and anti-androgenic changes even after discontinuation of the therapy. The study also presented data on penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of AGA. The study recommends additional clinical studies to assess non-sexual side effects that may persist after discontinuation of the drug and suggests that patients should be extensively counseled and monitored for possible side effects after initiation and discontinuation of this medication class.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results

    Related Community Posts Join

    6 / 1000+ results

      community How is dht not beneficial to you?

      in Finasteride/Dutasteride  111 upvotes 1 month ago
      DHT is important for sexual function and mood, but finasteride and dutasteride can reduce DHT, causing side effects like reduced libido and erectile dysfunction. These treatments are effective for hair loss, but their impact on DHT leads to debate.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    4 / 4 results